Melanoma: Symptoms, Treatment & When to Seek Care

Cutaneous melanoma is a malignant neoplasm of melanocytes that often begins on sun-exposed skin but can arise on acral, mucosal, or occult sites. Unlike many keratinocyte carcinomas that grow largely by local extension, melanoma frequently gains access to lymphatic channels and the bloodstream once Breslow thickness and other primary-tumour features cross thresholds that alter biological behaviour. Mitotic rate, ulceration of the primary lesion, and satellite or in-transit disease further refine how oncologists interpret risk and choose between wide local excision alone, sentinel lymph node biopsy, completion lymphadenectomy in selected pathways, systemic therapy, radiation, or clinical trial enrolment.

Pathophysiologically, ultraviolet radiation–induced DNA damage, fair phototype genetics, innate immune surveillance failure, and somatic alterations in signalling pathways cooperate to permit clonal expansion and invasion. Nurses rarely need genotype detail at intake, yet recognising phrases such as “BRAF mutated” cues targeted therapy compatibility distinct from chemotherapy-only eras. Immune checkpoint blockade has recalibrated prognosis for metastatic disease, shifting ward vigilance toward colitis mimicry, endocrinopathy-associated fatigue, and pneumonitis that can overshadow tumour-related symptoms unless actively screened.

Care delivery therefore spans primary-care triage photographs, dermatology dermoscopy, surgical oncology margin planning, medical oncology toxicity clinics, palliative liaison, and community nursing for wound burdens after wide excisions or flap repairs. Embedding consistent skin assessment language—as well as clear safety-net instructions when patients await biopsy results—reduces fragmented follow-up.

AJCC/UICC staging for melanoma emphasises microscopic primary depth (Breslow thickness measured in millimetres), ulceration, satellite or microsatellite disease, sentinel and non-sentinel nodal tumour burden when nodes are involved, lactate dehydrogenase elevation in stage IV nomenclature, and standard TNM mapping of distant metastatic sites. Cross-sectional CT of chest/abdomen/pelvis, whole-body or regional PET-CT when indicated, and contrast brain MRI for neurological symptoms or high-risk presentations inform whether therapy remains locoregional or shifts to systemic control.

↔On a small screen, swipe or scroll sideways to see the full table.

Edition-specific TNM cut-offs evolve—use the synoptic pathology report and MDT letter as canonical, not ward mnemonics alone.

Early invasive melanoma may be asymptomatic aside from a subtly altered changing mole or new solitary pigmented macule. Ward and clinic nurses often see patients referred after primary care photography, occupational health screens, or incidental discovery during dressing changes for unrelated wounds.

Typical clusters

• Lesions that violate ABCDE symmetry/border/colour rules or show rapid evolution—even if diameter remains modest.
• New dark streaks beneath nails without trauma (acral clue), unexplained ulceration bleeding on a pigmented background, or satellite pigmented macules around a dominant lesion.
• Palpable firm nodes in the epitrochlear, axillary, cervical, or inguinal basins matching the limb or trunk primary laterality.
• Constitutional symptoms when advanced disease accelerates: fatigue disproportionate to sleep, drenching sweats, or unexplained weight loss.

Atypical or site-specific cues

• Amelanotic pink nodules mimicking pyogenic granuloma—biopsy threshold stays low when growth is relentless.
• Mucosal lesions presenting as non-healing oral or genital patches with pigment variation.
• Ocular/visual changes from choroidal melanoma—not every pigmented lesion is epidermal.
• Diffuse rash after immunotherapy that heralds eruption-grade dermatologic immune-related adverse events.

Older adults may attribute spots to age; people with richly pigmented baseline skin tones may perceive colour change late—paired total-body comparisons and partner-assisted checks tighten detection when self-examination is unreliable.

Intermittent high-intensity ultraviolet exposure precipitates DNA damage disproportionate compared with chronic low-grade exposure—a pattern explaining heightened risk among fair-skinned individuals with blistering childhood sunburns or indoor ultraviolet tanning histories. Genetic variants reducing protective melanin density, congenital naevus syndromes, and familial melanoma clusters from CDKN2A and related loci widen phenotypic risk beyond sun behaviour alone. Immunosuppression after transplantation or longstanding biologic therapies impairs tumour surveillance.

• Modifiable: Indoor tanning cessation, habitual broad-spectrum photoprotection, shade-seeking behaviours during midday UV peaks.
• Partially modifiable: Outdoor occupational education (hat/sleeves), vitamin D supplementation plans when counselling patients to minimise burning while maintaining bone health targets per local guideline.
• Non-modifiable: Fitzpatrick skin type I–II phenotype, blistering childhood sunburn count, advancing age, dense naevus counts, germline predisposition syndromes.

Discussing ultraviolet drivers remains clinically tethered because secondary prevention lowers future keratinocyte and melanoma risk in survivors—frame advice as oncology safety behaviour, not generic wellness tips.

Clinical assessment

Structured history captures evolution timeline, prior blistering burns, family melanoma history, immunosuppression, and total-body skin survey for additional primaries. Examination maps the lesion within skin cancer risk zones, palpates regional nodes, and screens for in-transit dermal deposits. Dermoscopy, when accessible, informs referral urgency but never replaces biopsy for definitive invasive disease.

Laboratory investigations

Baseline complete blood count, renal function, and liver function tests support systemic therapy clearance; lactate dehydrogenase may appear on staging synoptic reports. These tests do not diagnose early primary melanoma but shape infusion safety once stage shifts.

Imaging

• High-resolution photography in curated pathways aids longitudinal comparison when lesions are observed briefly under specialist plans.
• Cross-sectional staging imaging follows MDT protocols once invasive depth, nodal status, or symptoms justify distant survey.
• Brain MRI is prioritised when focal neurology, seizures, or high-risk stage triggers guideline-mandated CNS evaluation.

Biopsy and pathology

Skin biopsy via excisional or punch technique that includes vertical depth allows Breslow measurement; shave samples risk understaging. Immunohistochemistry supports classification; somatic mutation panels inform targeted therapy when metastatic disease emerges. Tie pre-biopsy anticoagulant planning to local dermatology surgery standards.

• Risk-stratify the lesion: Apply ABCDE plus patient risk context; avoid “watch another year” when evolution is documented in high-risk hosts.
• Capture depth-quality biopsy: Coordinate excisional/punch sampling with clear margin intent notes so pathology can measure true thickness.
• Stage locoregional disease: Map nodes clinically; discuss sentinel lymph node biopsy when stage and fitness align with national guidance.
• Stage systemically when indicated: Commission CT/PET/MRI bundles per risk category before committing to major surgery or IO.
• MDT-select therapy: Assign wide local excision margins, completion nodes, radiotherapy fields, adjuvant IO, targeted therapy, or trial slots.
• Operationalise follow-up: Pair dermatoscopic skin surveillance intervals with patient-reported node checks; book IO laboratory monitoring before discharge teaching finishes.

• Benign compound or dysplastic naevi—stable dermoscopic patterns and absent evolution across serial images.
• Seborrhoeic keratosis with “stuck-on” morphology and uniform keratotic surface (still biopsy if rapid change confounds exam).
• Lentigo simplex or solar lentigo without architectural disorder on expert review.
• Vascular lesions (haemangioma, angiokeratoma) blanching with pressure or showing uniform red lacunae on dermoscopy.
• Pigmented basal cell variants or squamous lesions masquerading as melanoma—histology discriminates.

When doubt persists after specialist review, err toward biopsy rather than prolonged observation—documentation of shared decision conversations protects patients and clinicians alike.

↔On a small screen, swipe or scroll sideways to see the full table.

First-line locoregional management

Wide local excision with peripheral margins sized to Breslow category and national protocol underpins stage 0–II management; sentinel lymph node biopsy enters discussion for intermediate-thickness primaries without palpable adenopathy when fitness and patient values align. Therapeutic lymph node dissection or radiotherapy to nodal basins follows MDT selection after positive sentinel results or bulky clinical nodes. Nurses prepare patients for wound care, drain teaching when applicable, and suture removal timing per surgical teams.

Adjuvant and metastatic systemic therapy

Checkpoint inhibitors such as pembrolizumab feature in adjuvant programmes for node-positive or high-risk cutaneous primaries depending on approvals and formulary selections. Stage III unresectable and stage IV melanoma typically combines programmed death–1 or programmed death ligand–1 blockade ± cytotoxic T-lymphocyte–associated protein 4 inhibition when protocols match fitness; BRAF V600–mutated disease permits combined BRAF/MEK targeted tablets with distinct toxicity patterns (febrile reactions, hepatic enzymes, ophthalmologic symptoms).

Second-line considerations

Progression prompts trial enrolment, alternate IO combinations, targeted switches, or isolated metastasis ablation (surgery, stereotactic radiotherapy). Cytotoxic chemotherapy holds a diminished but occasionally useful niche guided by oncology rather than empirical ward initiation.

Special populations

Pregnancy demands teratogenic drug avoidance and multidisciplinary obstetric oncology planning. Severe hepatic impairment or active autoimmune disorders may disqualify checkpoint therapy—verification lives in prescribing governance, not nurse-led dose changes. Older adults tolerate IO but experience higher infection risk once prednisone courses escalate—glycaemia and mood surveillance matter.

• Pre-surgical: Mark biopsy sites clearly in handover; reconcile antithrombotics with dermatologic surgery timelines.
• IO clinics: Issue wallet cards listing immune-toxicity symptom triggers; book paired liver enzyme laboratory panels with infusion dates per protocol.
• Inpatient holds: Never restart checkpoint inhibitors after toxicity admission until written oncology approval—note temporary high-alert medication administration checks for IV biologics.
• Follow-up cadence: Stage I may visit every 3–12 months early post-resection per local guideline; metastatic cohorts tighten to cycles aligned with systemic therapy (~2–6 weeks initially).
• Referral escalation: New palpable nodes, neurologic deficits, doubling pain on opioids, or bilirubin rise during targeted therapy warrants same-day clinician alert.
• MDT coordination: Ensure dermatology/oncology/palliative notes synchronise Goals of Care summaries when prognosis shifts abruptly after progression imaging.

• In-transit and satellite metastases along dermal lymphatics causing fungating wounds or lymphoedema after nodal clearance.
• Immune-related hepatitis, pancreatitis-inspired enzyme rises, adrenal insufficiency from hypophysitis.
• Infection superimposed on chronic steroid-treated immune toxicity.
• Deep venous thromboembolism during prolonged inpatient debility.
• Treatment-associated psychological crisis when visible disfigurement or rapid functional loss emerges.

Secondary prevention after index melanoma focuses on rigorous scheduled total-skin examination, patient and partner education on self-detected changes, and photography for high-count naevus phenotypes within dermatology pathways. Behavioural ultraviolet minimisation—including eliminating sunbeds and reducing intentional tanning—pairs with pragmatic vitamin D supplementation discussions so patients do not paradoxically chase unsafe sun doses.

Select high-risk germline cohorts merit formal surveillance programmes coordinated with genetics counselling when available rather than improvised annual reassurance alone.

Thin, non-ulcerated primaries confer excellent long-term survival when complete excision verifies clear margins without nodal disease. Ulcerated thick primaries or macroscopic nodal involvement shifts expectations toward vigilant surveillance and adjunctive systemic therapy prospects. Immunotherapy-era metastatic melanoma achieves durable responses for subsets but toxicity and resistance remain unpredictable—communicate interval scan dependencies and avoid promising fixed cure timelines.

• Photograph dressing fields when fungating disease leaks—objective records assist community teams and legal documentation.
• Screen IO patients for “new headaches” and subtle personality changes; brain metastases can present atypically.
• Teach patients to palpate nodal basins with clean hands after showering; log dimensions in diaries supplied by clinics.
• Pair interpreter services for safety-net advice when English fluency is limited—written translated leaflets still need teach-back.
• Flag financial toxicity early; travel to tertiary melanoma centres strains working-age adults and may silently drive missed appointments.

• Skin & wounds: Measure exudate, note odour, photograph borders when policy allows, escalate spreading cellulitis.
• Immune toxicity: Stool frequency, abdominal distension, oxygen requirement, cough character, rash extent %BSA, morning corticosteroid doses already issued.
• Fluids & nutrition: Weight trends, oral intake with mucositis or nausea, IV access patency for contrast days.
• Neuro: GCS trend, seizure precautions, pupil checks if intracranial mass history.
• Psychosocial: Sleep, carer fatigue, suicidal ideation screening when diagnosis is new or prognosis shifts.

• First-time seizure or sudden focal weakness.
• Profuse gastrointestinal bleeding melena alongside checkpoint therapy.
• Rapid airway swelling or stridor—with or without infusion timing.
• Spinal pain with new urinary retention suggesting cord compression.

Follow local ED activation pathways; relay drug exposure timeline including last IO infusion date.

Worsening pain out of proportion to lesion size, escalating oxygen requirement after previously stable pulmonary imaging, stepwise abdomen distension during IO, or night sweats relapse after response phase should trigger structured assessment—not delayed “observe until clinic.”

• Escalate to senior clinician when NEWS/early-warning thresholds breach unexpectedly.
• Activate rapid response for seizures, airway compromise, or shock.
• Notify acute oncology when suspected grade ≥3 immune colitis, hepatitis, pneumonitis, or endocrine crisis—pair with pharmacist for concurrent medication interactions.

Pre-treatment education

Clarify biopsy-to-definitive-surgery timelines, sentinel node radioactive tracer expectations, fertility implications of investigational chemotherapy when relevant, and the difference between benign naevus excision melanoma bundles. Reinforce sunscreen behaviour without sounding dismissive of patient cultural norms.

During systemic therapy

Use infusion pre-assessment bundles verifying recent labs; teach delayed diarrhoea red flags versus mild functional stool change; reinforce steroid taper adherence when discharged on oral courses after toxicity admission. Maintain meticulous documentation of symptom onset timestamps for tumour board discussions.

Survivorship and palliative liaison

Coordinate lymphoedema services after groin dissection, scar massage when surgical teams approve, lymphatic drainage referrals, and early specialist palliative care for symptom-heavy metastatic journeys without implying withdrawal of anticancer therapy.

Nursing-priority lens (NCSBN Clinical Judgment Measurement Model): recognise cues → analyse cues → prioritise hypotheses → generate solutions → take safe action → evaluate outcomes. These NCLEX-style clinical judgment practice items practise priority activation after suspicious pigmented lesions, SATA reasoning around ABCDE escalation, immune-toxicity deterioration patterns, oncology triage, ordered responses along biopsy-to-MDT pathways, matrix matching of escalation tier, and a cloze on Breslow/sentinel-node vocabulary plus IO surveillance expectations—aligned with contemporary melanoma oncology teaching.